Bayesian methods for evidence synthesis in cost-effectiveness analysis

[1]  A. Culyer,et al.  Mark versus Luke? Appropriate Methods for the Evaluation of Public Health Interventions , 2007 .

[2]  S. Chick,et al.  A taxonomy of model structures for economic evaluation of health technologies. , 2006, Health economics.

[3]  David R. Jones,et al.  How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS , 2005, Statistics in medicine.

[4]  Simon G. Thompson,et al.  Meta‐Analysis of Clinical Trials , 2005 .

[5]  M. Sculpher,et al.  Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. , 2005, Health economics.

[6]  Laura Ginnelly,et al.  Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service? , 2005, International journal of cardiology.

[7]  M Sculpher,et al.  Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. , 2005, Health technology assessment.

[8]  Nicky J Welton,et al.  A model of toxoplasmosis incidence in the UK: evidence synthesis and consistency of evidence , 2005 .

[9]  P Wainwright,et al.  Virtual outreach: a randomised controlled trial and economic evaluation of joint teleconferenced medical consultations. , 2004, Health technology assessment.

[10]  G. Lu,et al.  Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.

[11]  G. Molenberghs,et al.  A perspective on surrogate endpoints in controlled clinical trials , 2004, Statistical methods in medical research.

[12]  Jan P Vandenbroucke,et al.  When are observational studies as credible as randomised trials? , 2004, The Lancet.

[13]  M Sculpher,et al.  A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. , 2004, Health technology assessment.

[14]  Lex M Bouter,et al.  Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes--implications for cost-effectiveness analyses. , 2004, International journal of epidemiology.

[15]  P Barton,et al.  The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. , 2004, Health technology assessment.

[16]  David Turner,et al.  Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach. , 2004, Health economics.

[17]  M. Zwahlen,et al.  Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials , 2004, BMJ : British Medical Journal.

[18]  N. G. Best,et al.  Bayesian approaches to multiple sources of evidence and uncertainty in complex cost‐effectiveness modelling , 2003, Statistics in Medicine.

[19]  A E Ades,et al.  A chain of evidence with mixed comparisons: models for multi‐parameter synthesis and consistency of evidence , 2003, Statistics in medicine.

[20]  Kerrie Mengersen,et al.  Multivariate meta‐analysis , 2003, Statistics in medicine.

[21]  Douglas G Altman,et al.  Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses , 2003, BMJ : British Medical Journal.

[22]  K R Abrams,et al.  Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section , 2002, Statistical methods in medical research.

[23]  Keith R Abrams,et al.  Generalized synthesis of evidence and the threat of dissemination bias. the example of electronic fetal heart rate monitoring (EFM). , 2002, Journal of clinical epidemiology.

[24]  M. Drummond,et al.  A rational framework for decision making by the National Institute For Clinical Excellence (NICE) , 2002, The Lancet.

[25]  Anne Whitehead,et al.  Meta-Analysis of Controlled Clinical Trials , 2002 .

[26]  Ron Goeree,et al.  Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux Disease , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[27]  A E Ades,et al.  Markov Chain Monte Carlo Estimation of a Multiparameter Decision Model: Consistency of Evidence and the Accurate Assessment of Uncertainty , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[28]  R. Taylor,et al.  NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE (NICE) , 2002, International Journal of Technology Assessment in Health Care.

[29]  A. Connor,et al.  The way I see it: House officers need formal career development , 2002 .

[30]  Giovanni Parmigiani,et al.  Modeling in Medical Decision Making: A Bayesian Approach , 2002 .

[31]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[32]  R. Peto,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[33]  J Hjelmgren,et al.  Health economic guidelines--similarities, differences and some implications. , 2001, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[34]  David R. Jones,et al.  Hierarchical models in generalized synthesis of evidence: an example based on studies of breast cancer screening. , 2000, Statistics in medicine.

[35]  S G Thompson,et al.  Analysing the relationship between treatment effect and underlying risk in meta-analysis: comparison and development of approaches. , 2000, Statistics in medicine.

[36]  J. Williamson,et al.  Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials , 2000, The Lancet.

[37]  R J Carroll,et al.  On meta-analytic assessment of surrogate outcomes. , 2000, Biostatistics.

[38]  G. Guyatt,et al.  Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials , 2000, BMJ : British Medical Journal.

[39]  A. Hartz,et al.  A comparison of observational studies and randomized, controlled trials , 2000, American journal of ophthalmology.

[40]  J. Concato,et al.  Randomized, controlled trials, observational studies, and the hierarchy of research designs. , 2000, The New England journal of medicine.

[41]  C. Ham.  Health services research methods: a guide to best practice , 2000 .

[42]  T. Fleming,et al.  Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. , 1999, JAMA.

[43]  David H. Krantz,et al.  Analysis of Local Decisions Using Hierarchical Modeling, Applied to Home Radon Measurement and Remediation , 1999 .

[44]  William DuMouchel,et al.  Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .

[45]  R. Klein,et al.  A Bayesian approach to modelling the natural history of a chronic condition from observations with intervention. , 1999, Statistics in medicine.

[46]  Gordon B. Hazen,et al.  A Bayesian approach to sensitivity analysis. , 1999, Health economics.

[47]  J Lipscomb,et al.  Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. , 1999, Journal of clinical epidemiology.

[48]  F Mosteller,et al.  Meta-analysis of multiple outcomes by regression with random effects. , 1998, Statistics in medicine.

[49]  M J Campbell,et al.  Choosing between randomised and non-randomised studies: a systematic review , 1998, BMJ.

[50]  John C. Hershey,et al.  Carrier Screening for Cystic Fibrosis , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[51]  A A Stinnett,et al.  Net Health Benefits , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[52]  V. Hasselblad,et al.  Meta-analysis of Multitreatment Studies , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[53]  M J Daniels,et al.  Meta-analysis for the evaluation of potential surrogate markers. , 1997, Statistics in medicine.

[54]  Sylvia Richardson,et al.  Markov Chain Monte Carlo in Practice , 1997 .

[55]  A Whitehead,et al.  Borrowing strength from external trials in a meta-analysis. , 1996, Statistics in medicine.

[56]  D. DeMets,et al.  Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.

[57]  C S Berkey,et al.  Multiple-outcome meta-analysis of clinical trials. , 1996, Statistics in medicine.

[58]  L. Hedges,et al.  The Handbook of Research Synthesis , 1995 .

[59]  V Hasselblad,et al.  Meta-analytic Tools for Medical Decision Making: A Practical Guide , 1995, Medical decision making : an international journal of the Society for Medical Decision Making.

[60]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.

[61]  Colin B. Begg,et al.  Random Effects Models for Combining Results from Controlled and Uncontrolled Studies in a Meta-Analysis , 1994 .

[62]  E. Chelimsky,et al.  Cross-design Synthesis: A New Form of Meta-analysis for Combining Results from Randomized Clinical Trials and Medical-practice Databases , 1993, International Journal of Technology Assessment in Health Care.

[63]  R. Simon,et al.  Bayesian subset analysis. , 1991, Biometrics.

[64]  M F Drummond,et al.  Economic Analysis Alongside Clinical Trials: Revisiting the Methodological Issues , 1991, International Journal of Technology Assessment in Health Care.

[65]  S. Ellenberg.  Surrogate end points in clinical trials. , 1991, BMJ.

[66]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[67]  K. Bailey,et al.  Inter-study differences: how should they influence the interpretation and analysis of results? , 1987, Statistics in medicine.

[68]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[69]  K E Willard,et al.  Probabilistic Analysis of Decision Trees Using Monte Carlo Simulation , 1986, Medical decision making : an international journal of the Society for Medical Decision Making.

[70]  D P Byar,et al.  Assessing apparent treatment--covariate interactions in randomized clinical trials. , 1985, Statistics in medicine.

[71]  B. McNeil,et al.  Probabilistic Sensitivity Analysis Using Monte Carlo Simulation , 1985, Medical decision making : an international journal of the Society for Medical Decision Making.

[72]  M. A. Best.  Bayesian Approaches to Clinical Trials and Health‐Care Evaluation , 2005 .

[73]  David J. Spiegelhalter,et al.  WinBUGS user manual version 1.4 , 2003 .

[74]  P C Lambert,et al.  A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. , 2002, Journal of clinical epidemiology.

[75]  K R Abrams,et al.  Bayesian methods in meta-analysis and evidence synthesis. , 2001, Statistical methods in medical research.

[76]  The National Institute for Clinical Excellence. , 2001, Nursing management.

[77]  C Bain,et al.  Choosing between randomised and non-randomised studies: a systematic review. , 1998, Health technology assessment.

[78]  William R. Shadish,et al.  Combining estimates of effect size. , 1994 .

[79]  David M. Eddy,et al.  Meta-analysis by the confidence profile method , 1992 .

[80]  R. Simon,et al.  Bayesian subset analysis in a colorectal cancer clinical trial. , 1992, Statistics in medicine.